title: A Randomized Clinical Trial Investigating the Effect of Particle Size of Calcium Sodium Phosphosilicate (CSPS) on the Efficacy of CSPS-containing Dentifrices for the Relief of Dentin Hypersensitivity.
abstract: OBJECTIVE
  To investigate the effect of reducing the particle size of calcium sodium phosphosilicate (CSPS) bioactive glass from ~14 µm (NovaMin®) to ~4 µm (Vitryxx®), and of changing the fluoride source in a 5% CSPS dentifrice from sodium monofluorophosphate (SMFP) to sodium fluoride (NaF) on the efficacy of CSPS-containing dentifrices in dentin hypersensitivity (DH) relief.
  
  
  METHODS
  A randomized, controlled, examiner-blind, five-treatment arm, parallel group, stratified, exploratory study of NaF dentifrices containing 2.5% or 5% small particle size CSPS (~4 µm), NaF or SMFP dentifrices containing 5% CSPS (~14 µm), and a regular fluoride dentifrice in healthy subjects with DH. Sensitivity to tactile stimulus (Yeaple probe) and evaporative (air) stimulus (Schiff Sensitivity Scale, visual analogue scale) was assessed at baseline and after one, two, four, and eight weeks' twice-daily treatment. The study was not statistically powered to detect significant between-treatment differences.
  
  
  RESULTS
  One hundred thirty-three of 134 randomized subjects completed the study. All treatments showed similar, statistically significant (p < 0.007) improvements in DH compared to baseline at Weeks 2, 4, and 8. No trends favoring any specific treatment were observed. Treatments were generally well tolerated.
  
  
  CONCLUSIONS
  The apparent absence of a positive treatment effect for the CSPS-containing dentifrices compared to the regular fluoride dentifrice is inconsistent with other previously reported efficacy studies for CSPS dentifrices.
authors.affiliation: GSK Consumer Healthcare, Shanghai, P.R. China.
authors.forename: Peng
authors.initials: P
authors.lastname: Zang
authors.affiliation: GSK Consumer Healthcare, Weybridge, Surrey, UK.
authors.forename: Charles
authors.initials: C
authors.lastname: Parkinson
authors.affiliation: GSK Consumer Healthcare, Weybridge, Surrey, UK.
authors.forename: Claire
authors.initials: C
authors.lastname: Hall
authors.affiliation: GSK Consumer Healthcare, Weybridge, Surrey, UK.
authors.forename: Nan
authors.initials: N
authors.lastname: Wang
authors.affiliation: School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, P.R. China.
authors.forename: Han
authors.initials: H
authors.lastname: Jiang
authors.affiliation: School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, P.R. China.
authors.forename: Jing
authors.initials: J
authors.lastname: Zhang
authors.affiliation: School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei, P.R. China.
authors.forename: Minquan
authors.initials: M
authors.lastname: Du
mesh_terms: D002118:Calcium; D003802:Dentifrices / Q000494:pharmacology*; D057133:Dentin Desensitizing Agents / Q000494:pharmacology*; D003807:Dentin Sensitivity; D004311:Double-Blind Method; D005459:Fluorides; D006801:Humans; D010316:Particle Size; D012964:Sodium; D012969:Sodium Fluoride; D016896:Treatment Outcome
chemical_list: D003802:Dentifrices; D057133:Dentin Desensitizing Agents; D012969:Sodium Fluoride; D012964:Sodium; D005459:Fluorides; D002118:Calcium
keywords: NovaMin; calcium sodium phosphosilicate; clinical trial; dentin hypersensitivity; particle size